rs104894578
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000891.3(KCNJ2):c.652C>T(p.Arg218Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R218L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000891.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
KCNJ2 | NM_000891.3 | c.652C>T | p.Arg218Trp | missense_variant | 2/2 | ENST00000243457.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
KCNJ2 | ENST00000243457.4 | c.652C>T | p.Arg218Trp | missense_variant | 2/2 | 1 | NM_000891.3 | P1 | |
KCNJ2 | ENST00000535240.1 | c.652C>T | p.Arg218Trp | missense_variant | 2/2 | 1 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 10, 2018 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 28, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 04, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Functional studies demonstrate a damaging effect: the variant causes a loss of function and a dominant negative effect on channel function when expressed with the wild-type protein (Plaster et al., 2001; Lange et al. 2003; Caballero et al., 2010); Also known as Kir2.1; This variant is associated with the following publications: (PMID: 12163457, 17568571, 17211524, 23631430, 20647529, 11371347, 25415519, 23867365, 15269659, 17119796, 18554214, 28501311, 12796536, 17221872, 22589293, 29093808, 15852530, 16217063, 17399642, 22581653, 28024840, 31068157, 31567646, 34008892, 35460302, 33057326, 20713726, 12909315) - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Andersen Tawil syndrome Pathogenic:4Other:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 18, 2001 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Jan 18, 2018 | PM2, PM5, PP2, PP3, PP4, PP5 - |
Pathogenic, criteria provided, single submitter | case-control | Genetics Laboratory, Department of Biology, Semnan University | Jan 06, 2020 | The identified mutation leads to the substitution of Arginine 218 with Tryptophan (R218W) in the KCNJ2 protein. Hence, this substitution alters the amino acid sequence and leads to a missense mutation at position 218 with possible increased function in the mutated protein. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Likely pathogenic, criteria provided, single submitter | research | Center of Excellence for Medical Genomics, Chulalongkorn University | Oct 05, 2022 | - - |
Andersen Tawil syndrome;C1865018:Short QT syndrome type 3 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 12, 2023 | ClinVar contains an entry for this variant (Variation ID: 8919). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNJ2 protein function. Experimental studies have shown that this missense change affects KCNJ2 function (PMID: 12909315, 17119796, 17568571). For these reasons, this variant has been classified as Pathogenic. This missense change has been observed in individual(s) with Andersen-Tawil syndrome (PMID: 12796536, 17119796, 17221872, 22589293). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 218 of the KCNJ2 protein (p.Arg218Trp). - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 19, 2022 | The c.652C>T (p.R218W) alteration is located in exon 2 (coding exon 1) of the KCNJ2 gene. This alteration results from a C to T substitution at nucleotide position 652, causing the arginine (R) at amino acid position 218 to be replaced by a tryptophan (W). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported in multiple unrelated patients with Andersen-Tawil syndrome (Plaster, 2001; Donaldson, 2003; Davies, 2005; Tengan, 2006; Haruna, 2007; Kimura, 2012; Lefter, 2014). In addition, an alteration affecting the same amino acid, p.R218Q was reported as disease-causing (Plaster, 2001; Kimura, 2012; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. Experimental studies have shown that this missense change alters KCNJ2 channel assembly and has a dominant negative effect on channel function (Lange, 2003; Decher, 2007). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Congenital long QT syndrome Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported in the following publications (PMID:11371347;PMID:12163457;PMID:12796536;PMID:15852530;PMID:16217063;PMID:17074642;PMID:17119796;PMID:17221872;PMID:17399642;PMID:18554214;PMID:20647529). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at